## Gilles W De Keulenaer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4425217/publications.pdf Version: 2024-02-01

		53794	22832
132	13,064	45	112
papers	citations	h-index	g-index
132	132	132	14959
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 2011, 364, 11-21.	27.0	2,491
2	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal, 2007, 28, 2539-2550.	2.2	2,302
3	Oscillatory and Steady Laminar Shear Stress Differentially Affect Human Endothelial Redox State. Circulation Research, 1998, 82, 1094-1101.	4.5	567
4	Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation, 2002, 106, 2961-2966.	1.6	551
5	Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine, 2013, 368, 1210-1219.	27.0	462
6	Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 312-324.	4.1	390
7	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 1-10.	7.1	350
8	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2013, 309, 1125.	7.4	297
9	Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease. Circulation, 2007, 116, 954-960.	1.6	230
10	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
11	Effect of a telemonitoringâ€facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMAâ€HF 1 (TElemonitoring) Tj ETQq1	1 <b>0.7</b> 8431	4 <b>1§</b> ₿T /Ove
12	Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1370-H1377.	3.2	183
13	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
14	The Vulnerability of the Heart As a Pluricellular Paracrine Organ. Circulation Research, 2010, 106, 35-46.	4.5	177
15	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
16	Vitamin D3-up-regulated Protein-1 Is a Stress-responsive Gene That Regulates Cardiomyocyte Viability through Interaction with Thioredoxin. Journal of Biological Chemistry, 2002, 277, 26496-26500.	3.4	159
17	Effects of the longâ€ŧerm administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure, 2012, 14, 219-225.	7.1	158
18	Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talk. Journal of Biological Chemistry. 2006, 281, 19469-19477.	3.4	154

#	Article	IF	CITATIONS
19	Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. European Heart Journal, 2015, 36, 1049-1058.	2.2	139
20	Vitamin D 3 –Upregulated Protein-1 (VDUP-1) Regulates Redox-Dependent Vascular Smooth Muscle Cell Proliferation Through Interaction With Thioredoxin. Circulation Research, 2002, 91, 689-695.	4.5	136
21	Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. European Heart Journal, 2015, 36, 2050-2060.	2.2	126
22	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
23	Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO. Frontiers in Physiology, 2018, 9, 382.	2.8	121
24	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
25	Systolic and Diastolic Heart Failure Are Overlapping Phenotypes Within the Heart Failure Spectrum. Circulation, 2011, 123, 1996-2005.	1.6	114
26	Cardiac endothelium and myocardial function. Cardiovascular Research, 1998, 38, 281-290.	3.8	107
27	Role of autophagy in heart failure associated with aging. Heart Failure Reviews, 2010, 15, 423-430.	3.9	103
28	Neuregulin-1 Induces a Negative Inotropic Effect in Cardiac Muscle. Circulation, 2004, 109, 324-326.	1.6	99
29	Angiotensin Il–Induced Hypertension Increases Heme Oxygenase-1 Expression in Rat Aorta. Circulation, 1997, 96, 1923-1929.	1.6	98
30	Convergence of Redox-Sensitive and Mitogen-Activated Protein Kinase Signaling Pathways in Tumor Necrosis Factor-α–Mediated Monocyte Chemoattractant Protein-1 Induction in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 385-391.	2.4	85
31	<i>Bmpr2</i> Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation, 2019, 139, 932-948.	1.6	74
32	Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovascular Research, 2014, 104, 423-431.	3.8	70
33	ErbB2 signaling at the crossing between heart failure and cancer. Basic Research in Cardiology, 2016, 111, 60.	5.9	68
34	Systolic and diastolic heart failure: Different phenotypes of the same disease?. European Journal of Heart Failure, 2007, 9, 136-143.	7.1	66
35	Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biological Chemistry, 2011, 392, 189-98.	2.5	66
36	Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H931-H942.	3.2	66

#	Article	IF	CITATIONS
37	The role of ErbB4 in cancer. Cellular Oncology (Dordrecht), 2020, 43, 335-352.	4.4	66
38	The cardiac endothelium: Functional morphology, development, and physiology. Progress in Cardiovascular Diseases, 1996, 39, 239-262.	3.1	65
39	Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1. Circulation Research, 2018, 123, 342-355.	4.5	64
40	Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H934-H945.	3.2	63
41	Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. Revista Portuguesa De Cardiologia, 2013, 32, 395-409.	0.5	62
42	Identification of IEX-1 as a Biomechanically Controlled Nuclear Factor-κB Target Gene That Inhibits Cardiomyocyte Hypertrophy. Circulation Research, 2002, 90, 690-696.	4.5	58
43	Diastolic heart failure: a myth. Current Opinion in Cardiology, 2006, 21, 240-248.	1.8	57
44	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal, 2013, 34, 3117-3127.	2.2	53
45	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovascular Research, 2018, 114, 880-893.	3.8	52
46	Therapeutic potential of neuregulin-1 in cardiovascular disease. Drug Discovery Today, 2013, 18, 836-842.	6.4	49
47	Activation of Cardiac Endothelium as a Compensatory Component in Endotoxin-Induced Cardiomyopathy. Circulation, 2001, 104, 3137-3144.	1.6	45
48	Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure. Circulation: Heart Failure, 2019, 12, e006288.	3.9	44
49	Chronic intermittent mental stress promotes atherosclerotic plaque vulnerability, myocardial infarction and sudden death in mice. Atherosclerosis, 2015, 242, 288-294.	0.8	42
50	Vascular smooth muscle cell contraction and relaxation in the isolated aorta: a critical regulator of large artery compliance. Physiological Reports, 2019, 7, e13934.	1.7	41
51	The Heart Failure Spectrum. Circulation, 2009, 119, 3044-3046.	1.6	40
52	Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics. International Journal of Molecular Sciences, 2012, 13, 12268-12286.	4.1	40
53	Update on pathophysiology and preventive strategies of anthracyclineâ€induced cardiotoxicity. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 204-215.	1.9	39
54	Long-term impact of a six-month telemedical care programme on mortality, heart failure readmissions and healthcare costs in patients with chronic heart failure. Journal of Telemedicine and Telecare, 2019, 25, 286-293.	2.7	37

#	Article	IF	CITATIONS
55	Diastolic Heart Failure: A Separate Disease or Selection Bias?. Progress in Cardiovascular Diseases, 2007, 49, 275-283.	3.1	36
56	Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction. Current Opinion in Cardiology, 2012, 27, 273-280.	1.8	36
57	A novel setâ€up for the <i>ex vivo</i> analysis of mechanical properties of mouse aortic segments stretched at physiological pressure and frequency. Journal of Physiology, 2016, 594, 6105-6115.	2.9	36
58	Biomechanically Induced Gene iex-1 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation. Circulation Research, 2003, 93, 1210-1217.	4.5	35
59	Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure. Experimental Hematology, 2007, 35, 1884-1890.	0.4	35
60	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. Frontiers in Pediatrics, 2020, 8, 342.	1.9	35
61	Endothelin-Mediated Positive Inotropic Effect Induced by Reactive Oxygen Species in Isolated Cardiac Muscle. Circulation Research, 1995, 76, 878-884.	4.5	35
62	Prevalence, Characteristics, and Predictors of Pulmonary Vein Narrowing After Isolation Using the Pulmonary Vein Ablation Catheter. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 52-60.	4.8	34
63	Pulmonary arterial hypertension: Basic knowledge for clinicians. Archives of Cardiovascular Diseases, 2016, 109, 550-561.	1.6	34
64	Molecular diversity of cardiac endothelial cells in vitro and in vivo. Physiological Genomics, 2004, 19, 198-206.	2.3	33
65	Applanation Tonometry in Mice. Hypertension, 2014, 64, 195-200.	2.7	33
66	Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. Cardiovascular Research, 2016, 109, 44-54.	3.8	33
67	Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H533-H539.	3.2	32
68	Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Pflugers Archiv European Journal of Physiology, 2008, 455, 811-818.	2.8	32
69	Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E495-E504.	3.5	32
70	Neuregulin-1 attenuates stress-induced vascular senescence. Cardiovascular Research, 2018, 114, 1041-1051.	3.8	32
71	Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clinical Neurology and Neurosurgery, 2013, 115, 1088-1093.	1.4	31
72	Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 395-409.	0.2	30

5

#	Article	lF	CITATIONS
73	Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. Journal of Molecular and Cellular Cardiology, 2009, 46, 33-38.	1.9	29
74	Autocrine Signaling in Cardiac Remodeling: A Rich Source of Therapeutic Targets. Journal of the American Heart Association, 2021, 10, e019169.	3.7	28
75	The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function. European Journal of Heart Failure, 2017, 19, 603-614.	7.1	27
76	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
77	Urocortin 2 in cardiovascular health and disease. Drug Discovery Today, 2015, 20, 906-914.	6.4	25
78	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (REDâ€HF). European Journal of Heart Failure, 2013, 15, 334-341.	7.1	24
79	The role of endothelial autocrine NRG1/ERBB4 signaling in cardiac remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H443-H455.	3.2	23
80	The role of endothelial miRNAs in myocardial biology and disease. Journal of Molecular and Cellular Cardiology, 2020, 138, 75-87.	1.9	20
81	Impact of Radiofrequency Characteristics on Acute Pulmonary Vein Reconnection and Clinical Outcome After PVAC Ablation. Journal of Cardiovascular Electrophysiology, 2013, 24, 290-296.	1.7	19
82	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. Cardiovascular Research, 2018, 114, 1165-1177.	3.8	19
83	Ex vivo aortic stiffness in mice with different eNOS activity. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1233-H1244.	3.2	18
84	Endocardial endothelial dysfunctionand heart failure. Journal of Cardiac Failure, 1996, 2, S195-S202.	1.7	17
85	Dilated Cardiomyopathy: Changing Pathophysiological Concepts and Mechanisms of Dysfunction. Journal of Cardiac Surgery, 1999, 14, 64-74.	0.7	17
86	Effect of angiotensin II-induced arterial hypertension on the voltage-dependent contractions of mouse arteries. Pflugers Archiv European Journal of Physiology, 2016, 468, 257-267.	2.8	17
87	Short-Term Angiotensin II Treatment Affects Large Artery Biomechanics and Function in the Absence of Small Artery Alterations in Mice. Frontiers in Physiology, 2018, 9, 582.	2.8	16
88	Physiopharmacological evaluation of myocardial performance how to study modulation by cardiac endothelium and related humoral factors?. Cardiovascular Research, 1998, 39, 136-147.	3.8	15
89	Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology, 2010, 99, 75-82.	3.3	14
90	Pulmonary vein stenosis after pulmonary vein ablation catheter–guided pulmonary vein isolation. Heart Rhythm, 2010, 7, 1306-1308.	0.7	14

6

#	Article	IF	CITATIONS
91	Endogenous inhibitors of hypertrophy in concentric versus eccentric hypertrophy. European Journal of Heart Failure, 2007, 9, 352-356.	7.1	13
92	Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biology of Sex Differences, 2020, 11, 47.	4.1	12
93	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e006898.	3.9	12
94	Reappraisal of the Multicellular Preparation for the In Vitro Physiopharmacological Evaluation of Myocardial Performance. Advances in Experimental Medicine and Biology, 1998, 453, 441-451.	1.6	12
95	Neuregulinâ€1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 255-265.	1.9	11
96	Cardiomyopathy and thyrotoxicosis. Acta Cardiologica, 2006, 61, 115-117.	0.9	11
97	Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension. Biomolecules, 2022, 12, 484.	4.0	11
98	Cardiac endothelial cell transcriptome in neonatal, adult, and remodeling hearts. Physiological Genomics, 2019, 51, 186-196.	2.3	9
99	Epigenetic regulation of intercellular communication in the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1417-H1425.	3.2	9
100	Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H2416-H2428.	3.2	8
101	Letter Regarding Article by Okoshi et al, "Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of β-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion― Circulation, 2005, 111, e175; author reply e175.	1.6	7
102	Pathophysiology of diastolic dysfunction in chronic heart failure. Future Cardiology, 2013, 9, 711-720.	1.2	7
103	Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential. Cardiovascular Drugs and Therapy, 2019, 33, 599-613.	2.6	7
104	Mobile cardiology during the COVID-19 outbreak. Cardiovascular Research, 2020, 116, e149-e151.	3.8	7
105	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. European Journal of Pharmacology, 2020, 889, 173658.	3.5	7
106	Effects of Nebivolol on Vascular Endothelial and Myocardial Function in Diabetes Mellitus. Journal of Cardiovascular Pharmacology, 2011, 58, 56-64.	1.9	6
107	A special case of hypertrophic cardiomyopathy with a differential diagnosis of isolated cardiac amyloidosis or junctophilin type 2 associated cardiomyopathy. Acta Clinica Belgica, 2021, 76, 136-143.	1.2	6
108	Endocardial endothelium modulates subendocardial pHi of rabbit papillary muscles: role of transendothelial HCO3? transport. Cardiovascular Research, 2004, 63, 700-708.	3.8	5

#	Article	IF	CITATIONS
109	<i>Paving new paths for neuregulin-1-assisted cardiac regenerative medicine</i> . Focus on "Improving murine embryonic stem cell differentiation into cardiomyocytes with neuregulin-1: differential expression of microRNAâ€. American Journal of Physiology - Cell Physiology, 2011, 301, C16-C17.	4.6	5
110	Improvement in left intraventricular pressure gradients after aortic valve replacement in aortic stenosis patients. Experimental Physiology, 2017, 102, 411-421.	2.0	5
111	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	5
112	Decreased myocardial contractility after damage to endocardial endothelium is not merely caused by loss of endothelin production. Cardiovascular Research, 1995, 30, 646-647.	3.8	4
113	Inhibition of heme oxygenase?1 impairs cardiac muscle sensitivity to beta?adrenergic stimulation. Basic Research in Cardiology, 2005, 100, 224-230.	5.9	4
114	Letter by Brutsaert and De Keulenaer Regarding Article, "Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fractionâ€: Circulation: Heart Failure, 2015, 8, 839-839.	3.9	3
115	Scientists on the Spot: Inflammation in atherosclerosis. Cardiovascular Research, 2021, 117, e7-e8.	3.8	2
116	Avalanching nanoparticles bring new light to cardiovascular imaging. Cardiovascular Research, 2021, 117, e60-e63.	3.8	1
117	Cardiotoxicity of Cancer Chemotherapy–Recent Developments. , 2016, , 36-83.		1
118	Urgent need to reorganize heart failure management. Acta Cardiologica, 2005, 60, 179-184.	0.9	1
119	Molecular Mechanisms of Diastolic Dysfunction. , 2008, , 3-19.		1
120	Pathophysiology of Heart Failure: Back to Basics. , 2013, , 3-23.		1
121	Urocortins as biomarkers in cardiovascular disease. Clinical Science, 2022, 136, 1-14.	4.3	1
122	Pulmonary Valve Replacement: A New Paradigm with Tissue Engineering. Current Problems in Cardiology, 2023, 48, 101212.	2.4	1
123	Dilated Cardiomyopathy: Changing Pathophysiological Concepts and Mechanisms of Dysfunction. Echocardiography, 1985, 2, 64-72.	0.9	0
124	HEART FAILURE WITH A PRESERVED EJECTION FRACTION: FROM PATHOPHYSIOLOGY TO BIOMARKERS $\hat{a} \in AND$ BEYOND!. The European Journal of Cardiovascular Medicine, 2011, I, .	1.0	0
125	DPP4 inhibition may ameliorate bone turnover in diabetic mice. Bone, 2012, 50, S171.	2.9	0
126	P505Neuregulin-1 ameliorates right ventricular diastolic dysfunction in pulmonary arterial hypertension. Cardiovascular Research, 2014, 103, S92.4-S92.	3.8	0

#	Article	IF	CITATIONS
127	P755Molecular mechanisms underlying the beneficial effects of neuregulin-1 in pulmonary arterial hypertension. Cardiovascular Research, 2014, 103, S138.3-S138.	3.8	Ο
128	Highlights of American Heart Association Scientific Sessions 2020: a virtual experience. Cardiovascular Research, 2021, 117, e10-e12.	3.8	0
129	Scientist on the Spot: Exploring the cause and cure for pulmonary arterial hypertension. Cardiovascular Research, 2021, 117, e82-e83.	3.8	Ο
130	145 Gene transfer of the mechanically induced gene IEX-I inhibits cardiac hypertrophy in vivo. European Heart Journal, 2003, 24, 12.	2.2	0
131	Normal Physiology and Pathophysiology of Left Ventricular Diastole. , 2008, , 52-62.		Ο
132	Endocardial—Myocardial Interaction. , 1997, , 163-178.		0